Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Grants and contracts	$ 922,202	$ 1,138,187
Operating expenses:
Research and development	1,656,427	3,619,103
General and administrative	1,817,830	2,318,990
Total operating expenses	3,474,257	5,938,093
Loss from operations	(2,552,055)	(4,799,906)
Other income (expense):
Interest and other income (expense)	(681,503)	126,127
Foreign exchange gain (loss)	(1,329)	3,514
Change in value of warrant liability	72,223	962,818
Total other income (expense)	(610,609)	1,092,459
Net loss	(3,162,664)	(3,707,447)
Net loss attributable to noncontrolling interests	47,677	95,474
Net loss attributable to Cleveland BioLabs, Inc.	$ (3,114,987)	$ (3,611,973)
Net loss available to common stockholders per share of common stock, basic and diluted (in dollars per share)	$ (0.28)	$ (0.32)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)	11,298,239	11,293,842